tial effect, 3.0 (2.8) days (range, 1-7 days) for BT-B vs 14.3 (6.7) days (range, 7-20 days) for BT-A. Anhidrotic areas developed earlier in the BT-B side. Patients reported longer-lasting subjective benefit from BT-B than BT-A: 17.3 (7.4) weeks vs 12.9 (8.4) weeks.All patients tolerated intradermally injected BT-A and BT-B well, although some experienced mild pain, especially during BT-B injections. No hematomas developed at the injection site, nor did any participant report systemic adverse effects.

Over the past several years, tumor necrosis factor (TNF) antagonists have become first-line agents in the treatment of moderate-to-severe psoriasis. These medications are highly effective in treating both psoriasis and psoriatic arthritis and may also reduce the risk of cardiovascular events in patients with chronic inflammatory disorders. In this article we review the use of anti-TNF therapy in psoriasis and its implications in regards to the co-morbid conditions associated with psoriasis.

No abstract

No abstract